In late-November 2021, the Omicron variant of SARS-CoV-2 (the virus which causes COVID-19) was designated as a variant of concern by the World Health Organization due to fears about a higher transmissibility from the variant and a possible decrease in the effectiveness of vaccines against it.
Source: Statista
Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...
Read more
